An Open-Label Treatment Option of Brentuximab Vedotin in

Project: Research project

Project Details

Description

An Open-label treatment otion of Brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma or relapsed or refractory systemic anaplastic large cell lymphoma.
StatusFinished
Effective start/end date3/15/113/15/13

Funding

  • Seattle Genetics, Inc.

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.